Rate My Professor Philip Adamson

Adamson's clinical practice focuses on treating coronary and structural heart diseases through interventions such as coronary stenting, transcatheter aortic valve implantation, patent foramen ovale closure, and left atrial appendage occlusion. His research centers on coronary artery disease encompassing angina and acute coronary syndrome, valvular heart disease including aortic stenosis and mitral regurgitation, stroke prevention, and cardiac computed tomography. He emphasizes diagnostic and prognostic assessments of cardiovascular disease via circulating and imaging biomarkers, particularly advanced cardiac CT techniques. Adamson secures two project grants from the Health Research Council of New Zealand for multicentre trials exploring novel treatments for acute coronary syndromes. He also participates as an investigator in studies evaluating new devices for minimally invasive structural heart disease and stroke prevention therapies. With over 9,600 citations on Google Scholar, his influential publications from the SCOT-HEART trial include 'Coronary CT angiography and 5-year risk of myocardial infarction' (New England Journal of Medicine, 2018), 'Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial' (Circulation, 2020), and 'Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study' (Journal of the American College of Cardiology, 2019). Recent contributions cover the RELEVENT trial and left atrial appendage occlusion evaluations. He acts as Associate Editor for Heart, The BMJ.